<PAGE>
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Dated December 1, 1999
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Translation of registrant's name into English)
2350 Cohen Street
-----------------
Saint Laurent, Quebec Canada H4R 2N6
------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ______ Form 40-F X (commenced in calendar
----- year 1998)
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ____ No X
---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Registrant)
Date: December 1, 1999 By: /s/ David Moszkowski
----------------- -----------------------------------
David Moszkowski
Senior Vice President and
Chief Financial Officer
<PAGE>
Exhibit 99.1
PHOENIX INTERNATIONAL RE-ALIGNS
GLOBAL OPERATIONS
-- Company is focused on the integration of its global operations to better
serve its customers and realize improved operating efficiencies --
Montreal, Quebec - November 29, 1999 - Phoenix International Life Sciences Inc.
(NASDAQ: PHXI; TSE/ME: PHX), one of the world's top five Contract Research
Organizations (CROs), today announced that it is re-aligning its global
operations to better serve its international customers, improve its operating
efficiencies and meet anticipated future growth in demand for its services.
Under the direction of recently appointed CEO, Ian Lennox, Phoenix International
will now comprise four fully integrated global service units:
. Discovery and Preclinical Services, headed by Dr. Nigel Brown;
. Global Analytical and Phase I Services, headed by Dr. Stephane Huguet;
. Clinical Research, Americas, headed by Dr. Susan Thornton;
. Clinical Research, Europe/Asia, headed by Dr. Lucien Steru.
Phoenix International's new service units will be supported by David Moszkowski,
Finance, Tax, & Treasury, George Engelberg, Information Technology, and a small
corporate services group.
"Our new business structure will enable better allocation of people and capital
as we shift the company from a geographically independent group of business
entities, to a fully integrated, global CRO," said Ian Lennox. "The re-alignment
will offer our customers improved access to our global services."
This new strategic organizational structure is designed to consolidate and
leverage the company's acquisitions to improve its overall operations and
profitability. Customer service will be enhanced through greater flexibility,
improved efficiencies and better allocation of resources.
-- more --
<PAGE>
About Phoenix International
Phoenix International is one of the world's leading contract research
organizations. The Company provides a wide spectrum of clinical, analytical,
preclinical, drug discovery support and ancillary services to the pharmaceutical
and biotechnology industries. Since beginning its operations in 1989, Phoenix
International has grown to approximately 2,400 employees worldwide, of whom more
than 215 have either medical degrees or PhD's and over 240 others have masters
level education. Headquartered in Montreal, Quebec, Phoenix International has
operations throughout Europe and North America and research facilities in
Australia, Israel and South Africa. Phoenix International is on the World Wide
Web at www.pils.com.
------------
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
FOR MORE INFORMATION, PLEASE CONTACT:
Richard Gareau
Director, Corporate Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033
Fax: (514) 333-8861
E-mail: [email protected]
<PAGE>
Exhibit 99.2
PRESS RELEASE
PHOENIX INTERNATIONAL RE-ALIGNS UK OPERATIONS
MONTREAL, QUEBEC - NOVEMBER 30, 1999 - Phoenix International Life Sciences Inc.
(NASDAQ: PHXI; TSE/ME: PHX), one of the world's top five Contract Research
Organizations (CROs), announced today that it is re-aligning its UK operations
to improve efficiency and better serve the future needs of its customers.
This local initiative is a further development of the Company's global re-
alignment into four fully-integrated service units. The UK operations will be
relocating to a more accessible site closer to Heathrow Airport and its key
customers to accommodate its growing international business.
'The UK re-alignment will continue the building of our strong management team
and business development capabilities in the United Kingdom. These changes will
provide the foundation to accommodate profitable growth,' said Ian Lennox, Chief
Executive Officer of Phoenix International.
Commenting on the initiative, Lucien Steru, Head of Clinical Research,
Europe/Asia, Phoenix International, stated: 'This re-alignment will ensure that
as we grow, we will continue to provide our customers with efficient, high
quality services. Our new facility will be better located and will enable us to
recruit additional highly qualified staff.'
Simon Yaxley, recently appointed Managing Director of Phoenix's UK operations,
will spearhead the drive to establish a stronger operation in the UK. Currently,
the Romford operations employ over 75 specialized staff working in Phase II-IV
clinical trials, in ClinQA, the independent in-house quality assurance division,
and Rostrum the training division.
About Phoenix International
Phoenix International is one of the world's leading contract research
organizations. The Company provides a wide spectrum of clinical, analytical,
preclinical, drug discovery support and ancillary services to the pharmaceutical
and biotechnology industries. Since beginning its operations in 1989, Phoenix
International has grown to approximately 2,400 employees worldwide, of whom more
than 215 have either medical degrees or PhD's and over 240 others have masters
level education. Headquartered in Montreal, Quebec, Phoenix International has
operations throughout Europe and North America and research facilities in
Australia, Israel and South Africa. Phoenix International is on the World Wide
Web at www.pils.com.
------------
<PAGE>
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
-30-
FOR MORE INFORMATION, PLEASE CONTACT:
Richard Gareau
Director, Corporate Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033
Fax: (514) 333-8861
E-mail:[email protected]
